JMP Securities Analysts Give Cytokinetics (NASDAQ:CYTK) a $23.00 Price Target

Share on StockTwits

Cytokinetics (NASDAQ:CYTK) has been assigned a $23.00 target price by investment analysts at JMP Securities in a report issued on Friday, The Fly reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. JMP Securities’ target price suggests a potential upside of 76.92% from the company’s current price.

Several other analysts have also weighed in on the company. Zacks Investment Research raised Cytokinetics from a “sell” rating to a “hold” rating in a research note on Thursday. Morgan Stanley set a $16.00 price objective on Cytokinetics and gave the company a “hold” rating in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective (up from $14.00) on shares of Cytokinetics in a research note on Friday, September 6th. BidaskClub lowered Cytokinetics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 16th. Finally, Needham & Company LLC set a $16.00 price objective on Cytokinetics and gave the company a “buy” rating in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Cytokinetics presently has a consensus rating of “Buy” and a consensus price target of $18.71.

NASDAQ:CYTK traded up $0.61 during trading hours on Friday, hitting $13.00. The company’s stock had a trading volume of 19,834 shares, compared to its average volume of 351,227. The stock has a fifty day simple moving average of $13.20 and a 200-day simple moving average of $10.36. The company has a market capitalization of $739.35 million, a P/E ratio of -6.67 and a beta of 1.64. The company has a debt-to-equity ratio of 12.35, a current ratio of 8.42 and a quick ratio of 8.42. Cytokinetics has a twelve month low of $5.75 and a twelve month high of $14.94.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.06). The business had revenue of $7.14 million during the quarter, compared to analyst estimates of $6.81 million. Cytokinetics had a negative net margin of 308.73% and a negative return on equity of 575.21%. On average, equities analysts predict that Cytokinetics will post -2 EPS for the current fiscal year.

In other Cytokinetics news, CEO Robert I. Blum sold 6,000 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $12.64, for a total value of $75,840.00. Following the completion of the transaction, the chief executive officer now directly owns 250,022 shares in the company, valued at $3,160,278.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 16,500 shares of company stock valued at $199,185 over the last quarter. Corporate insiders own 5.70% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CYTK. Bank of America Corp DE raised its position in Cytokinetics by 303.8% in the fourth quarter. Bank of America Corp DE now owns 43,462 shares of the biopharmaceutical company’s stock valued at $275,000 after purchasing an additional 32,699 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in Cytokinetics by 59,718.8% in the first quarter. BNP Paribas Arbitrage SA now owns 9,571 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 9,555 shares during the last quarter. Bank of Montreal Can raised its position in Cytokinetics by 109.5% in the first quarter. Bank of Montreal Can now owns 3,321 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,736 shares during the last quarter. SG Americas Securities LLC bought a new position in Cytokinetics in the first quarter valued at about $151,000. Finally, Comerica Bank raised its position in Cytokinetics by 3.5% in the first quarter. Comerica Bank now owns 54,154 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 1,808 shares during the last quarter. Hedge funds and other institutional investors own 74.57% of the company’s stock.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

See Also: Yield Curve

The Fly

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Citrix Systems, Inc.  Sees Large Decrease in Short Interest
Citrix Systems, Inc. Sees Large Decrease in Short Interest
Short Interest in Lowe’s Companies, Inc.  Drops By 20.6%
Short Interest in Lowe’s Companies, Inc. Drops By 20.6%
Randolph Bancorp Inc  Sees Large Decrease in Short Interest
Randolph Bancorp Inc Sees Large Decrease in Short Interest
Intuit Inc.  Short Interest Update
Intuit Inc. Short Interest Update
TenX Price Tops $0.11 on Major Exchanges
TenX Price Tops $0.11 on Major Exchanges
PopularCoin  Reaches Market Capitalization of $94,640.00
PopularCoin Reaches Market Capitalization of $94,640.00


© 2006-2019 Ticker Report